debt_leverage_profile
0.65x Total Debt / Equity (Moderate leverage)
High
SEC-XBRL
interest_rate_sensitivity
Moderate-high; Lifeward carries debt tied to medtech capital markets; 200bps rate rise increases annual interest burden ~$2-4M on ~$20M debt load
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Israel-based manufacturing exposed to Middle East conflict disruption; Taiwan/Asia semiconductor components for exoskeleton electronics represent second chokepoint
Inferred
Agent_Inference
international_expansion_readiness
Primary markets US, Germany, Japan; EUR and JPY devaluation vs USD compresses reported revenue ~5-12% given ~40% non-US sales mix
Inferred
Agent_Inference
geographic_footprint
US (~60%), Germany and Europe (~25%), Israel and ROW (~15%); EUR/JPY devaluation risk meaningful given non-hedged international invoicing practices
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; proprietary ReWalk exoskeleton hardware relies on limited actuator and battery suppliers; single-source components likely exceed 30% of COGS
Inferred
Agent_Inference
business_model_type_primary
Cloud dependency is low-moderate; core product is physical medtech hardware; cloud termination would disrupt data analytics and remote monitoring but not core device function
Inferred
Agent_Inference
business_model_type_secondary
Software/data layer (ReStore therapy platform) would face 30-day disruption risk but represents minority of revenue; hardware sales would continue unaffected
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; software platform is proprietary and not deeply integrated into third-party hospital EHR APIs at scale; limited ecosystem lock-in
Inferred
Agent_Inference
howey_test_risk_index
Very low; revenue model is medical device sales and service contracts; no investment-contract structure, token, or profit-sharing mechanism present
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; patient rehabilitation data collected in EU (Germany) triggers GDPR; US patient data under HIPAA not CCPA primarily; compliance infrastructure appears basic for company size
Inferred
Agent_Inference
antitrust_exposure_flag
Low; Lifeward holds <5% of global exoskeleton market; no dominant market position; Ekso Bionics and Ottobock provide competitive alternatives limiting monopoly concern
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (~70% device sales); recurring revenue from service contracts and SaaS therapy platform estimated ~20-30% of total revenue
Inferred
Agent_Inference
monetization_vector
Primary: capital equipment sales to rehab hospitals and VA; secondary: per-session or subscription therapy software and maintenance service contracts
Inferred
Agent_Inference
pricing_architecture
ASP ~$70-80K per ReWalk unit; reimbursement-dependent pricing; Medicare/VA coverage caps compress pricing power; limited ability to raise price without reimbursement code expansion
Inferred
Agent_Inference
pricing_power_rating
Low; pricing constrained by insurance reimbursement schedules and VA procurement rules; 3/10 pricing power rating in current reimbursement environment
Inferred
Agent_Inference
target_gross_margin_bracket
602.0% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; capital equipment requires purchase; however, low repeat-purchase frequency per customer creates revenue lumpiness and renewal risk on service contracts
Inferred
Agent_Inference
headcount_cost_structure
Largely headcount-linear; clinical training, regulatory, and sales teams must scale with geographic expansion; limited software leverage keeps growth model linear
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost; each new market requires clinical specialists, reimbursement navigation, and regulatory approval; doubling revenue likely requires ~70-80% headcount increase
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Lifeward operates direct sales and distribution model, not a franchise network
Inferred
Agent_Inference
customer_acquisition_metric
CAC estimated $80-150K per institutional client at current scale; at 10x scale, VA and large rehab network consolidation could reduce CAC 30-40% via channel efficiency
Inferred
Agent_Inference
network_effect_present
Weak; no meaningful network effect in hardware exoskeleton sales; data network effect nascent via ReStore platform outcomes database but not yet competitively differentiated
Inferred
Agent_Inference
asset_efficiency_ratio
-87.2% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-low; VA and Medicare budgets provide partial insulation but hospital capex cuts during recessions defer large equipment purchases; Tier 3 recession resistance
Inferred
Agent_Inference
customer_segment_primary
Inpatient rehabilitation hospitals and spinal cord injury centers (~50% of revenue); VA healthcare system represents significant concentrated government buyer
Inferred
Agent_Inference
customer_segment_secondary
VA medical centers (~25-30% of revenue); high concentration risk as VA contract modifications or budget freezes materially impact quarterly revenue
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
1.1% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001607962
High
SEC-EDGAR
ticker
LFWD
High
SEC-EDGAR